Skip to content
Search

Latest Stories

New study reveals how to ‘measure’ chronic pain using brain signals

New research has shown that chronic pain can be objectively measured using brain signals, a report in The Conversation said.

According to the report, a team of researchers conducted a study using brain implants capable of recording neural signals over an extended period.


Their aim was to identify reliable markers of chronic pain severity in four patients as they went about their daily lives.

While pain is typically a subjective experience, there is still much to discover about how pain signals are processed in the brain.

Previous studies often relied on artificial settings, and the relationship between acute and chronic pain circuits remained unclear.

To investigate this further, the researchers surgically implanted electrodes in the brains of four patients experiencing post-stroke pain and phantom limb pain.

Neural signals were recorded in specific brain regions associated with planning, expectation, and emotion.

The patients were then asked to report their pain severity levels multiple times a day for up to six months.

Machine learning models were developed to analyse the recorded brain activity signals and predict the patients’ self-reported pain intensity scores.

The findings unveiled a significant connection between low-frequency brain activity in the orbitofrontal cortex and the patients’ subjective pain intensities, providing an objective measure of chronic pain.

A greater shift in low-frequency activity indicated more intense pain.

Furthermore, a comparison between chronic pain and acute pain revealed distinct brain regions involved in processing each type of pain. This experiment shed light on the differences in information processing between acute and chronic pain.

Chronic pain affects a substantial portion of the population and has a higher prevalence than conditions like diabetes, high blood pressure, or depression. It poses challenges for effective treatment and can significantly impact both physical and emotional well-being.

Improved understanding of how to measure brain activity to track pain could lead to enhanced diagnosis and the development of novel treatments, such as deep brain stimulation.

While this study offers valuable insights into using specific brain regions as objective measures of chronic pain, there is still much more to uncover.

Pain signals are likely distributed across a wider brain network, and researchers are yet to determine other brain regions that may play vital roles in reflecting subjective pain.

Additionally, it remains uncertain whether the identified signals will apply to other types of pain conditions.

Looking ahead, the researchers aim to leverage these newly discovered neural biomarkers to create personalised brain stimulation approaches for treating chronic pain disorders.

This entails developing algorithms that incorporate the identified signals to govern the timing and location of brain stimulation, similar to how a thermostat operates.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less